JP2018514565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514565A5 JP2018514565A5 JP2017556902A JP2017556902A JP2018514565A5 JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5 JP 2017556902 A JP2017556902 A JP 2017556902A JP 2017556902 A JP2017556902 A JP 2017556902A JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5
- Authority
- JP
- Japan
- Prior art keywords
- depot
- vaccine
- seq
- forming
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 82
- 239000000427 antigen Substances 0.000 claims 45
- 102000036639 antigens Human genes 0.000 claims 45
- 108091007433 antigens Proteins 0.000 claims 44
- 230000015572 biosynthetic process Effects 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 230000028993 immune response Effects 0.000 claims 8
- 241000701806 Human papillomavirus Species 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- 108010002687 Survivin Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 239000012051 hydrophobic carrier Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000004543 DNA replication Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000003921 oil Substances 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- -1 cholesterol lipid Chemical class 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 239000002480 mineral oil Substances 0.000 claims 2
- 235000010446 mineral oil Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 206010022095 Injection Site reaction Diseases 0.000 claims 1
- 241000223810 Plasmodium vivax Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155677P | 2015-05-01 | 2015-05-01 | |
| US62/155,677 | 2015-05-01 | ||
| PCT/CA2016/050487 WO2016176761A1 (en) | 2015-05-01 | 2016-04-27 | Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514565A JP2018514565A (ja) | 2018-06-07 |
| JP2018514565A5 true JP2018514565A5 (OSRAM) | 2019-05-23 |
| JP6851983B2 JP6851983B2 (ja) | 2021-03-31 |
Family
ID=57217405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556902A Expired - Fee Related JP6851983B2 (ja) | 2015-05-01 | 2016-04-27 | デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180162913A1 (OSRAM) |
| EP (1) | EP3288538A4 (OSRAM) |
| JP (1) | JP6851983B2 (OSRAM) |
| WO (1) | WO2016176761A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972635A1 (en) | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
| CN109328070A (zh) | 2016-05-04 | 2019-02-12 | 免疫疫苗技术有限公司 | 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法 |
| TWI895621B (zh) | 2016-05-27 | 2025-09-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| EP3518963A4 (en) * | 2016-09-27 | 2020-06-10 | ImmunoVaccine Technologies Inc. | Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects |
| EP3582790A4 (en) * | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| CN109456405B (zh) * | 2017-09-06 | 2022-02-08 | 上海交通大学医学院附属仁济医院 | 一种去棕榈酰化pd-l1蛋白质及其制备方法和应用 |
| US20200353062A1 (en) * | 2017-11-09 | 2020-11-12 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof |
| CN107988373A (zh) * | 2018-01-10 | 2018-05-04 | 上海交通大学医学院附属仁济医院 | 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用 |
| WO2019178677A1 (en) * | 2018-03-20 | 2019-09-26 | Immunovaccine Technologies Inc. | Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes |
| MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
| US20220125903A1 (en) * | 2018-11-19 | 2022-04-28 | Immunovaccine Technologies Inc. | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
| WO2024186623A1 (en) | 2023-03-03 | 2024-09-12 | BioVaxys Inc. | Methods of making dried pharmaceutical compositions |
| WO2024186646A1 (en) | 2023-03-03 | 2024-09-12 | BioVaxys Inc. | Methods of making lipid adjuvanted compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| JP4516916B2 (ja) * | 2003-07-11 | 2010-08-04 | 昇志 佐藤 | リビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド |
| US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| AU2006210863A1 (en) * | 2005-02-01 | 2006-08-10 | Medivas, Llc. | Vaccine delivery compositions and methods of use |
| US7947286B2 (en) * | 2005-10-07 | 2011-05-24 | Panthera Biopharma Llc | Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain |
| CA2523032A1 (en) * | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| WO2009025770A2 (en) * | 2007-08-17 | 2009-02-26 | Wyeth | A heterologous prime-boost immunization regimen |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| JP5715051B2 (ja) * | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
| WO2011120045A1 (en) * | 2010-03-26 | 2011-09-29 | Emergent Product Development Gaithersburg Inc. | Ectodomains of influenza matrix 2 protein, expression system, and uses thereof |
| WO2014055289A1 (en) * | 2012-10-01 | 2014-04-10 | Thomas Jefferson University | Immunization with rabies virus vector expressing foreign protein antigen |
| ES2702622T3 (es) * | 2013-03-27 | 2019-03-04 | Immunovaccine Technologies Inc | Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer |
-
2016
- 2016-04-27 WO PCT/CA2016/050487 patent/WO2016176761A1/en not_active Ceased
- 2016-04-27 JP JP2017556902A patent/JP6851983B2/ja not_active Expired - Fee Related
- 2016-04-27 EP EP16788982.3A patent/EP3288538A4/en not_active Withdrawn
- 2016-04-27 US US15/571,003 patent/US20180162913A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514565A5 (OSRAM) | ||
| Yang et al. | Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases | |
| Moni et al. | Advancements in vaccine adjuvants: the journey from alum to nano formulations | |
| Facciolà et al. | An overview of vaccine adjuvants: current evidence and future perspectives | |
| Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
| Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
| Tornesello et al. | Nanoparticles to improve the efficacy of peptide-based cancer vaccines | |
| Cunningham et al. | Vaccine development: From concept to early clinical testing | |
| TWI672149B (zh) | 改良之疫苗組成物及使用方法 | |
| Gomes et al. | Harnessing nanoparticles for immunomodulation and vaccines | |
| JP2015522580A5 (OSRAM) | ||
| Martiñón et al. | Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants | |
| Alving et al. | Adjuvants for human vaccines | |
| JP2014520807A5 (OSRAM) | ||
| JP2018534304A5 (OSRAM) | ||
| Levast et al. | Vaccine potentiation by combination adjuvants | |
| Goetz et al. | Vaccine adjuvants for infectious disease in the clinic | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| Even-Or et al. | Adjuvanted influenza vaccines | |
| JP2014522842A5 (OSRAM) | ||
| RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
| JP2013181034A5 (OSRAM) | ||
| JP2014532620A5 (OSRAM) | ||
| Ireton et al. | Adjuvants containing natural and synthetic Toll-like receptor 4 ligands | |
| CN103768595B (zh) | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 |